This SciClone won't take you to Oz, but it has taken its drugs to China. The drug firm's flagship product Zadaxin is approved to treat hepatitis B in some 30 countries, including China, its primary market. Zadaxin also has uses in additional viral vaccines and cancer treatments. The drug has yet to receive the regulatory green light, however, in the world's two largest drug markets -- the US and the European Union (EU). SciClone is working with development partner Sigma-Tau to gain marketing approval in the US and EU; the company also wants to expand the use of the drug to include additional conditions. In the meantime, SciClone is seeking to commercialize additional products in the core Chinese market.